Publications by authors named "L Tapia Casado"

Article Synopsis
  • * Out of these patients, 8 experienced treatment intolerance with asciminib while 11 developed resistance; treatment strategies included dose adjustments of cTKIs or considering ponatinib despite previous non-candidacy.
  • * The overall survival rate was 73% with the best outcomes for those intolerant to drugs (100%), while patients who progressed to advanced stages had a notably low survival rate (25%).
View Article and Find Full Text PDF

Introduction: Poststroke hyperglycaemia is an independent risk factor for poorer outcomes in patients treated with mechanical thrombectomy (MT) and is associated with a lower probability of functional recovery and higher mortality at 3 months. This study aims to evaluate the association between glucose levels during cerebral reperfusion with MT and functional recovery at 3 months, measured by subcutaneous continuous glucose monitoring (CGM) devices.

Methods: This prospective observational study aims to recruit 100 patients with ischaemic stroke and large anterior circulation vessel occlusion, in whom MT is indicated.

View Article and Find Full Text PDF

Background: BTK inhibitors have been concurrently administered with anti-CD20 monoclonal antibodies (mAbs) in chronic lymphocytic leukemia (CLL). However, the optimal regimen for combining these two drugs remains pending.

Methods: This multi-center phase 2 study aimed to analyze whether consolidation with ofatumumab improved the response in patients with CLL receiving front-line treatment with ibrutinib.

View Article and Find Full Text PDF

Blast phase (BP) of chronic myeloid leukemia (CML) still represents an unmet clinical need with a dismal prognosis. Due to the rarity of the condition and the heterogeneity of the biology and clinical presentation, prospective trials and concise treatment recommendations are lacking. Here we present the analysis of the European LeukemiaNet Blast Phase Registry, an international collection of the clinical presentation, treatment and outcome of blast phases which had been diagnosed in CML patients after 2015.

View Article and Find Full Text PDF